Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
The round valued the AI biotech at $2 billion.
It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on techcrunch.com — the content belongs to TechCrunch.